RxDoctor Payments Data

Ketti Awad, MD

Internal Medicine · Houston, TXNPI 1740284710

Payments from drug & device makers

$21,007in general payments, 2019–2025

Across 1,416 payments — averaging $14.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$3K
  • AstraZeneca$2K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$987
  • plus $10K from 45 others

What the payments were for

  • Food & beverage$20,999100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,007 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$149,202
Medicare patients
299
Services billed
1,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide198$247,497
OzempicSemaglutide94$106,042
JardianceEmpagliflozin79$81,109
XareltoRivaroxaban14$29,451
Repatha SureclickEvolocumab28$14,695
EliquisApixaban11$12,872
SynthroidLevothyroxine Sodium112$9,858
Icosapent Ethyl11$6,313
Rosuvastatin Calcium312$4,728
Valsartan170$4,414
Atorvastatin Calcium397$4,338
Olmesartan Medoxomil130$3,123
PaxlovidNirmatrelvir/Ritonavir26$2,858
Omega-3 Acid Ethyl Esters26$2,593
Metformin Hcl ErMetformin Hcl175$2,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,295$247,497198 claims
Novo NordiskOzempic$2,955$106,04294 claims
Boehringer IngelheimJardiance$987$81,10979 claims
Johnson & JohnsonXarelto$647$29,45114 claims
PfizerEliquis, Paxlovid$925$15,73037 claims
AbbVieSynthroid$3,076$9,858112 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$2,354194 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →